MDGL
Income statement / Annual
Last year (2024), Madrigal Pharmaceuticals, Inc.'s total revenue was $180.13 M,
and the percentage change from the previous year is not available.
In 2024, Madrigal Pharmaceuticals, Inc.'s net income was -$465.89 M.
See Madrigal Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$180.13 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$6.23 M
|
$527.00 K
|
$0.00
|
$0.00
|
$471.00 K
|
$112.00 K
|
$96.00 K
|
$77.00 K
|
$156.00
|
$0.00
|
| Gross Profit |
$173.90 M
|
-$527.00 K
|
$0.00
|
$0.00
|
-$471.00 K
|
-$112.00 K
|
-$96.00 K
|
-$77.00 K
|
-$156.00
|
$0.00
|
| Gross Profit Ratio |
0.97
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$236.72 M
|
$271.82 M
|
$245.44 M
|
$205.16 M
|
$184.81 M
|
$72.32 M
|
$25.39 M
|
$24.39 M
|
$15.93 M
|
$54.22 M
|
| General & Administrative Expenses |
$0.00
|
$108.15 M
|
$48.13 M
|
$37.32 M
|
$21.86 M
|
$22.65 M
|
$15.29 M
|
$7.67 M
|
$9.29 M
|
$13.39 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$435.06 M
|
$108.15 M
|
$48.13 M
|
$37.32 M
|
$21.86 M
|
$22.65 M
|
$14.97 M
|
$7.67 M
|
$9.29 M
|
$13.39 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$671.78 M
|
$379.97 M
|
$293.57 M
|
$242.48 M
|
$205.85 M
|
$94.86 M
|
$40.36 M
|
$31.81 M
|
$24.98 M
|
$3.17 M
|
| Cost And Expenses |
$678.01 M
|
$380.50 M
|
$293.57 M
|
$242.48 M
|
$206.67 M
|
$94.97 M
|
$40.68 M
|
$32.06 M
|
$25.22 M
|
$67.61 M
|
| Interest Income |
$46.65 M
|
$19.58 M
|
$2.19 M
|
$363.00 K
|
$4.33 M
|
$11.02 M
|
$7.67 M
|
$558.00 K
|
$48.30 K
|
$0.00
|
| Interest Expense |
$14.67 M
|
$12.71 M
|
$3.96 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.16 M
|
$1.06 M
|
| Depreciation & Amortization |
$1.10 M
|
$527.00 K
|
$467.00 K
|
$405.00 K
|
$471.00 K
|
$112.00 K
|
$96.00 K
|
$77.00 K
|
$156.00
|
$2.58 K
|
| EBITDA |
-$450.13 M |
-$360.39 M |
-$290.92 M |
-$241.44 M |
-$201.77 M |
-$83.84 M |
-$32.72 M |
-$31.08 M |
-$25.18 M |
-$3.23 M |
| EBITDA Ratio |
-2.5
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-2.76
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$31.98 M
|
$6.87 M
|
-$1.78 M
|
$636.00 K
|
$4.08 M
|
$11.02 M
|
$7.65 M
|
$732.00 K
|
-$1.41 M
|
-$3.67 M
|
| Income Before Tax |
-$465.89 M
|
-$373.63 M
|
-$295.35 M
|
-$241.85 M
|
-$202.24 M
|
-$83.95 M
|
-$32.81 M
|
-$31.15 M
|
-$26.39 M
|
-$68.67 M
|
| Income Before Tax Ratio |
-2.59
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$465.89 M
|
-$373.63 M
|
-$295.35 M
|
-$241.85 M
|
-$202.24 M
|
-$83.95 M
|
-$32.81 M
|
-$31.15 M
|
-$26.39 M
|
-$6.84 M
|
| Net Income Ratio |
-2.59
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-21.9 |
-19.99 |
-17.23 |
-14.63 |
-13.09 |
-4.73 |
-2.22 |
-2.54 |
-5.07 |
-401.56 |
| EPS Diluted |
-21.9 |
-19.99 |
-17.23 |
-14.63 |
-13.09 |
-4.73 |
-2.22 |
-2.54 |
-5.07 |
-401.56 |
| Weighted Average Shares Out |
$21.27 M
|
$18.69 M
|
$17.14 M
|
$16.54 M
|
$15.45 M
|
$15.40 M
|
$14.80 M
|
$12.25 M
|
$5.21 M
|
$171.01 K
|
| Weighted Average Shares Out Diluted |
$21.27 M
|
$18.69 M
|
$17.14 M
|
$16.54 M
|
$15.45 M
|
$15.40 M
|
$14.80 M
|
$12.25 M
|
$5.21 M
|
$171.01 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
